Literature DB >> 25099616

EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma.

Marina Rolo Pinheiro da Rosa1, Aline Semblano Carreira Falcão, Hellen Thais Fuzii, Maria Sueli da Silva Kataoka, André L R Ribeiro, Enrique Boccardo, Adriane Sousa de Siqueira, Ruy G Jaeger, João de Jesus Viana Pinheiro, Sérgio de Melo Alves Júnior.   

Abstract

Ameloblastoma is an odontogenic tumor characterized by local invasiveness and frequent recurrence. The surrounding stroma, composed of different cell types and extracellular matrix (ECM), may influence ameloblastoma invasive behavior. Furthermore, tumor and stromal cells secrete matrix metalloproteases (MMPs), which, in turn, can modulate the matrix and promote the release of ECM-bound growth factors. Among these growth factors, epidermal growth factor (EGF) and its receptor, EGFR, have already been shown to stimulate MMP synthesis, suggesting that an interdependent mechanism, involving MMP activity and growth factors release, may contribute to tumor invasiveness. The aim of this study was to evaluate the effects of the EGF/EGFR signaling pathway on migration, invasion, and MMP activity, in a primary cell line derived from human ameloblastoma. We established and characterized a primary cell line (AME-1) from a human ameloblastoma sample. This cell line was transduced with human papillomavirus type 16 (HPV16) E6/E7 oncogenes, generating the AME-HPV continuous cell line. EGF, MMP2, and MMP9 expression in ameloblastoma biopsies and in the AME-HPV cell line was analyzed by immunohistochemistry and immunofluorescence, respectively. Migratory activity of EGF-treated AME-HPV cells was investigated using monolayer wound assays and Transwell chambers. EGF-induced invasion was assessed in Boyden chambers coated with Matrigel. Conditioned medium from EGF-treated cells was subjected to zymography. EGFR expression in AME-HPV cells was silenced by small interfering RNA (siRNA), to verify the relationship between this receptor and MMP secretion. Ameloblastoma samples and AME-HPV cells expressed EGF, EGFR, MMP2, and MMP9. AME-HPV cells treated with EGF showed increased rates of migration and invasion, as well as enhanced MMP2 and MMP9 activity. EGFR knockdown decreased MMP2 and MMP9 levels in AME-HPV cells. EGFR signaling downstream of EGF probably regulates migration, invasion, and MMP secretion of ameloblastoma-derived cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25099616     DOI: 10.1007/s13277-014-2401-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  53 in total

Review 1.  Matrix metalloproteinases and the regulation of tissue remodelling.

Authors:  Andrea Page-McCaw; Andrew J Ewald; Zena Werb
Journal:  Nat Rev Mol Cell Biol       Date:  2007-03       Impact factor: 94.444

Review 2.  The ameloblastoma: primary, curative surgical management.

Authors:  Eric R Carlson; Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2006-03       Impact factor: 1.895

3.  Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Authors:  John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

Review 4.  Friends or foes - bipolar effects of the tumour stroma in cancer.

Authors:  Margareta M Mueller; Norbert E Fusenig
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

5.  Presence of myofibroblasts and expression of matrix metalloproteinase-2 (MMP-2) in ameloblastomas correlate with rupture of the osseous cortical.

Authors:  Eduardo Rodrigues Fregnani; Lays M Sobral; Fabio Abreu Alves; Fernando Augusto Soares; Luis Paulo Kowalski; Ricardo D Coletta
Journal:  Pathol Oncol Res       Date:  2008-12-19       Impact factor: 3.201

6.  Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through Focal adhesion kinase.

Authors:  Bernard Rothhut; Christelle Ghoneim; Frank Antonicelli; Mahdhia Soula-Rothhut
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

7.  Local invasiveness of ameloblastoma. Role played by matrix metalloproteinases and proliferative activity.

Authors:  J J V Pinheiro; V M Freitas; A I S Moretti; A G Jorge; R G Jaeger
Journal:  Histopathology       Date:  2004-07       Impact factor: 5.087

8.  Immunohistochemical analysis of matrix metalloproteinases (1, 2, and 9), Ki-67, and myofibroblasts in keratocystic odontogenic tumors and pericoronal follicles.

Authors:  Grasieli de Oliveira Ramos; Aline Costa; Maria I Meurer; Daniella S C Vieira; Elena R C Rivero
Journal:  J Oral Pathol Med       Date:  2014-04       Impact factor: 4.253

9.  Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is regulated by epidermal growth factor receptor.

Authors:  Michael J Herr; Scott E Mabry; Jessica F Jameson; Lisa K Jennings
Journal:  Biochem Biophys Res Commun       Date:  2013-11-16       Impact factor: 3.575

10.  Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.

Authors:  Anita Lal; Chad A Glazer; Holly M Martinson; Henry S Friedman; Gary E Archer; John H Sampson; Gregory J Riggins
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  10 in total

1.  Proteomic profile of saliva and plasma from women with impalpable breast lesions.

Authors:  Lucas Delmonico; Maryah Bravo; Rafaele Tavares Silvestre; Maria Helena Faria Ornellas; Carolina Maria De Azevedo; Gilda Alves
Journal:  Oncol Lett       Date:  2016-07-08       Impact factor: 2.967

Review 2.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

3.  Molecular Signaling in Benign Odontogenic Neoplasia Pathogenesis.

Authors:  Hope M Amm; Mary MacDougall
Journal:  Curr Oral Health Rep       Date:  2016-03-31

4.  Nuclear localization of epidermal growth factor receptor (EGFR) in ameloblastomas.

Authors:  Núbia Braga Pereira; Ana Carolina de Melo do Carmo; Marina Gonçalves Diniz; Ricardo Santiago Gomez; Dawidson Assis Gomes; Carolina Cavalieri Gomes
Journal:  Oncotarget       Date:  2015

Review 5.  Genetic aspects of pituitary carcinoma: A systematic review.

Authors:  Zijiang Yang; Ting Zhang; Heng Gao
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

6.  pPeOp from Omphalia lapidescens Schroet induces cell cycle arrest and inhibits the migration of MC-4 gastric tumor cells.

Authors:  Yong-Le Yang; Wei-Yao Gong; Fei-Fei Chen; Lu-Chao Chen; Yi-Tao Chen
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

7.  Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation.

Authors:  Dahye Jang; Yu Mi Baek; Hanna Park; Yeo Eun Hwang; Dong-Eun Kim
Journal:  BMB Rep       Date:  2018-01       Impact factor: 4.778

8.  TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways.

Authors:  Yuanyuan Zhao; Jing Ma; Yanling Fan; Zhiyong Wang; Ran Tian; Wei Ji; Fei Zhang; Ruifang Niu
Journal:  Mol Oncol       Date:  2018-01-24       Impact factor: 6.603

9.  Antitumor Effect of Calcium-Mediated Destabilization of Epithelial Growth Factor Receptor on Non-Small Cell Lung Carcinoma.

Authors:  In Un Kim; In Sung Sung; Jae Jun Sim; Minhee Park; Keun-Yeong Jeong; Hwan Mook Kim
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923

10.  EGF stimulates glioblastoma metastasis by induction of matrix metalloproteinase-9 in an EGFR-dependent mechanism.

Authors:  Xing-Chen Chen; Xiang-Tai Wei; Jun-Hong Guan; Hong Shu; Duo Chen
Journal:  Oncotarget       Date:  2017-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.